Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Core Insights - Monopar Therapeutics Inc. announced that its abstract on MNPR-101-RIT has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress, highlighting the company's innovative approach in cancer treatment [1][3] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing treatments for cancer, including the Phase 1-stage MNPR-101-Zr for imaging and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for advanced cancers [4] Product Details - MNPR-101-RIT is a first-in-class radio-immuno-therapeutic targeting cancers with the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [2] - Preclinical data show significant anti-tumor benefits with MNPR-101 when conjugated to therapeutic radioisotopes like lutetium-177 (Lu-177) and actinium-225 (Ac-225) [2] Clinical Trials - The company has initiated a first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [3]